Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S243249 in Relapsed or Refractory Acute Leukemia
NCT07722312Phase 2Not yet recruiting
- Sponsor
- Servier
- Start
- Oct 2026
- Primary completion
- Aug 2029
01
Overview
A Phase 2 trial of S243249 in acute leukemia, acute myeloid leukemia (AML), sponsored by Servier. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
S243249
03
Conditions
acute leukemiaacute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07722312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07722312.